Back to Search
Start Over
Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations.
- Source :
-
Arzneimittel-Forschung [Arzneimittelforschung] 1991 Dec; Vol. 41 (12), pp. 1237-41. - Publication Year :
- 1991
-
Abstract
- The effects of KW-3635 (sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate, CAS 127166-41-0) on smooth muscle preparations were examined. In isolated guinea-pig aorta, KW-3635 competitively inhibited the U-46619 (a thromboxane mimetic) induced contractions (pA2 = 7.74), the effect being more potent than those of sulotroban and daltroban. In canine saphenous vein, KW-3635 also antagonized the U-46619-induced contraction (pA2 = 8.11). In this preparation, solutroban and daltroban, but not KW-3635, exhibited intrinsic agonistic action. KW-3635, even at a high concentration of 10(-5) mol/l did not affect the norepinephrine- or KCl-induced contractions of guinea-pig or rat aorta, prostaglandin (PG)E2- or PGF2 alpha-induced contractions of guinea-pig ileum nor the PGE2-induced contraction of rat fundus. KW-3635 at concentrations higher than its thromboxane A2- (TxA2-)antagonistic one, non-competitively inhibited the PGF2 alpha-induced contractions of guinea-pig aorta (pD2' = 6.23), as was the case with daltroban. The inhibitory effect of KW-3635 (3 x 10(-6) mol/l) on U-46619-induced contractions of guinea-pig aorta persisted for longer than 2 h following washout of the tissue, whereas that of daltroban (10(-5) mol/l completely disappeared at 1 h after the washout. In anesthetized guinea-pigs, KW-3635 at doses of 10 to 1000 micrograms/kg (i.v.) inhibited U-46619 (1 microgram/kg i.v.)-induced pressor responses in a dose-dependent manner. The effect of KW-3635 (0.1 to 1 mg/kg i.v.) persisted for longer than 3 h. These results demonstrate that KW-3635 is a potent and specific TxA2 antagonist without agonistic action in vascular smooth muscles. KW-3635 is considered to be a promising candidate for the treatment of patients with disorders mediated via TxA2.
- Subjects :
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Animals
Blood Pressure drug effects
Cats
Dogs
Female
Guinea Pigs
In Vitro Techniques
Male
Muscle Contraction drug effects
Muscle, Smooth, Vascular drug effects
Phenylacetates pharmacology
Platelet Aggregation Inhibitors pharmacology
Prostaglandin Endoperoxides, Synthetic antagonists & inhibitors
Prostaglandin Endoperoxides, Synthetic pharmacology
Rabbits
Rats
Rats, Inbred Strains
Species Specificity
Sulfonamides pharmacology
Benzimidazoles pharmacology
Benzoxepins pharmacology
Muscle, Smooth drug effects
Thromboxane A2 antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 0004-4172
- Volume :
- 41
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Arzneimittel-Forschung
- Publication Type :
- Academic Journal
- Accession number :
- 1815522